IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis

Area of Science:

• Immunology
• Neuroscience
• Gerontology

Background:

• Late-onset multiple sclerosis (MS) often leads to progressive disability.
• Aging-associated immune changes, including senescence-associated secretory phenotype (SASP) and elevated IL-6, contribute to MS pathogenesis.
• Effective treatments for elderly MS patients are lacking.

Purpose of the Study:

• To investigate the preclinical efficacy of interleukin-6 (IL-6) signaling inhibition in an aged mouse model of MS.
• To evaluate IL-6 blockade as a potential age-specific therapeutic strategy for elderly MS patients.

Main Methods:

• Experimental autoimmune encephalomyelitis (EAE) was induced in young and aged mice using myelin oligodendrocyte protein (MOG)35-55.
• Mice received anti-IL-6 antibody treatment.
• Neurological signs, spinal cord inflammation, and peripheral immune responses (T cell populations, inhibitory checkpoints) were analyzed.

Main Results:

• IL-6 blockade did not ameliorate the clinical progression of EAE in aged mice.
• However, IL-6 inhibition increased the frequency of IL-10 producing CD4 T cells.
• Increased expression of PD-1 and Tim-3 on CD4+ T cells, and Lag-3 and Tim-3 on CD8+ T cells was observed.

Conclusions:

• Therapeutic IL-6 inhibition alone is insufficient to improve EAE outcomes in an aging context.
• IL-6 blockade enhances peripheral immunosuppressive mechanisms, offering a basis for further research.
• Optimizing anti-IL-6 treatment strategies may lead to effective age-specific therapies for elderly MS patients.